Genetic dimorphism in superoxide dismutase and susceptibility to alcoholic cirrhosis, hepatocellular carcinoma, and death  Pierre Nahon, Angéla Sutton, Dominique Pessayre, Pierre Rufat, Francoise Degoul, Nathalie Ganne-Carrie, Marianne Ziol, Nathalie Charnaux, Gisèle N’Kontchou, Jean-Claude Trinchet, Liliane Gattegno, Michel Beaugrand  Clinical Gastroenterology and Hepatology  Volume 3, Issue 3, Pages 292-298 (March 2005) DOI: 10.1016/S1542-3565(04)00718-9 Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 1 Frequency of HCC development in alcoholic patients classified according to the MnSOD genotype. χ2 test, P = .02. VV, Val/Val patients; AV, Ala/Val patients; AA, Ala/Ala patients. Clinical Gastroenterology and Hepatology 2005 3, 292-298DOI: (10.1016/S1542-3565(04)00718-9) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 2 Time to occurrence of HCC according to the MnSOD genotype, as assessed with the Kaplan-Meier method. Log-rank test, P = .009; Cox model, P = .014. The median time to occurrence of HCC was more than 180 months in Val/Val homozygotes, 153 months in Ala/Val heterozygotes, and 139 months in Ala/Ala homozygotes. In Cox multivariate analysis including age and sex, the relative risk for HCC occurrence in patients with at least 1 Ala allele was 4.59 (95% CI, 1.61–13.06) compared with Val/Val patients. Clinical Gastroenterology and Hepatology 2005 3, 292-298DOI: (10.1016/S1542-3565(04)00718-9) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 3 Frequency of death (or liver transplantation) in cirrhotic alcoholic patients classified according to the MnSOD genotype. χ2 test, P = .03. VV, Val/Val patients; AV, Ala/Val patients; AA, Ala/Ala patients. Clinical Gastroenterology and Hepatology 2005 3, 292-298DOI: (10.1016/S1542-3565(04)00718-9) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 4 Survival distribution function without liver transplantation according to the MnSOD genotype, as assessed with the Kaplan-Meier method. Log-rank test, P = .008; Cox model, P = .01. The median survival was 249 months in Val/Val homozygotes, 81 months in Ala/Val heterozygotes, and 82 months in Ala/Ala homozygotes. In Cox multivariate analysis including age and sex, the relative risk for death in patients with at least 1 Ala allele was 2.49 (95% CI, 1.36–4.57) compared with patients with the Val/Val MnSOD genotype. Clinical Gastroenterology and Hepatology 2005 3, 292-298DOI: (10.1016/S1542-3565(04)00718-9) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 5 Comparison of the MnSOD genotypic distribution in controls and in cirrhotic patients at inclusion (time of the first liver biopsy examination showing cirrhosis) and after 5 or 10 years of survival. Statistically significant differences were observed at inclusion, but were no longer observed in patients surviving for 5 or 10 years. VV, Val/Val patients; AV, Ala/Val patients; AA, Ala/Ala patients; n, number of patients. Clinical Gastroenterology and Hepatology 2005 3, 292-298DOI: (10.1016/S1542-3565(04)00718-9) Copyright © 2005 American Gastroenterological Association Terms and Conditions